Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the NF-B signal
Molecular Pharmacology, 10/19/09
Lee JH et al. – The data suggest that EGCG has an anti–osteoclastogenic effect by inhibiting RANKL–induced the activation of JNK/c–Jun and NF–kB pathways, thereby suppressing the gene expression of c–Fos and NFATc1 in osteoclast precursors.
Related Articles
MG-63 Osteoblast-like Cells Enhance the Osteoprotegerin Expression of PC-3 Prostate Cancer Cells
Anticancer Research, 11/10/09
Relevance Score: 85%
Association of serum osteoprotegerin with ankle-brachial index and urine albumin: Creatinine ratio in African-Americans and non-Hispanic whites
Atherosclerosis, 10/15/09
Relevance Score: 84%
Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing’s syndrome
European Journal of Endocrinology, 10/14/09
Relevance Score: 82%
Low serum osteoprotegerin levels in normoalbuminuric type 1 diabetes mellitus
Acta Diabetologia, 10/09/09
Relevance Score: 82%
A Single-Nucleotide Polymorphism in the Gene Encoding Osteoprotegerin Is Associated With Diastolic Blood Pressure in Older Men
American Journal of Hypertension, 10/28/09
Relevance Score: 80%
Today in Basic Science...keeping you current
Receive free subspecialty "5-minute updates" via email
Bupivacaine Inhibits Glutamatergic Transmission in Spinal Dorsal Horn Neurons
Anesthesiology, 12/11/09
Expectations, validity, and reality in pharmacogenetics
Journal of Clinical Epidemiology, 12/10/09
Inhibitory effects of 1,3-thiazine derivatives on melanogenesis
Journal of Pharmacy and Pharmacology, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


